Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Synexus

Neither a doctor nor a teaching hospital

Research payments

$1,568,648

713 payments

Through program year 2025, Synexus is reported as receiving $1,568,648 in research payments, across 713 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $33,288 6
2024 Research $210,829 59
2023 Research $374,778 283
2022 Research $383,435 236
2021 Research $51,484 19
2020 Research $117,874 39
2019 Research $396,960 71

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $524,054 4 payments
  2. Merck Sharp & Dohme Corporation $448,847 99 payments
  3. Janssen Research & Development, LLC $382,165 21 payments
  4. Avanir Pharmaceuticals, Inc. $116,144 23 payments
  5. Novartis Pharmaceuticals Corporation $58,929 5 payments
  6. Alnylam Pharmaceuticals Inc. $37,681 554 payments
  7. E.R. Squibb & Sons, L.L.C. $346 2 payments
  8. Pfizer Inc. $315 4 payments
  9. Moderna TX, Inc. $166 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $522,434 3 payments
  2. A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants $380,841 13 payments
  3. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE $287,692 41 payments
  4. 18-Avp-786-207 $116,144 23 payments
  5. Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $114,324 17 payments
  6. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $56,504 3 payments
  7. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $32,684 469 payments
  8. Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $19,775 17 payments
  9. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE $11,590 4 payments
  10. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE $7,715 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record